Evidence map›Paper›PMID 32319618›Full record

ArticleMolecular medicine reports2020

Glucagon‑like peptide‑1 analogue exendin‑4 modulates serotonin transporter expression in intestinal epithelial cells.

Xiufang Cui, Xiaojing Zhao, Ying Wang, Yan Yang, Hongjie Zhang

Open access · hybridAbstract read
In one paragraph

Article in Molecular medicine reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Irritable Bowel Syndrome Clinical Care Gaps and the Potential of Future Therapeutics Based on Peripheral Visceral Afferent Modulation.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2026
    Review
  2. Advances in GLP-1 receptor agonists for pain treatment and their future potential.The journal of headache and pain · 2025 · on this map
    Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Xiufang CuiDepartment of Gastroenterology, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China.
Xiaojing ZhaoDepartment of Gastroenterology, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China.
Ying WangDepartment of Gastroenterology, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China.
Yan YangDepartment of Gastroenterology, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China.
Hongjie ZhangDepartment of Gastroenterology, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China.
Jiangsu Province Hospital · CNNanjing Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Serotonin‑selective reuptake transporter (SERT) regulates extracellular availability of serotonin (5‑hydroxytryptamine; 5‑HT) and participates in the pathogenesis of functional disorders. Colonic SERT expression is decreased in colonic sensitized rats, and the glucagon‑like peptide‑1 analogue, exendin‑4, reduces visceral hypersensitivity by decreasing 5‑HT levels and increasing SERT expression. The present in vitro study aimed to further investigate the effects of exendin‑4 on SERT expression, and to examine the role of GLP‑1 and its receptor in the regulation of 5‑HT. SERT mRNA and protein expression levels were detected by reverse transcription‑quantitative PCR and western blotting. A [3H]‑5‑HT reuptake experiment was performed in IEC‑6 rat intestinal epithelial cells treated with exendin‑4. Effects on the adenosine cyclophosphate (AC)/PKA pathway were examined by variously treating cells with the AC activator forskolin, the protein kinase A (PKA) inhibitor H89 and the AC inhibitor SQ22536. Exendin‑4 treatment upregulated SERT expression and enhanced 5‑HT reuptake in IEC‑6 cells. Also, PKA activity in IEC‑6 cells was increased by both exendin‑4 and forskolin, whereas these effects were abolished by the pre‑treatment of exendin‑9, which is a GLP‑1R inhibitor, SQ22536 and H89. In conclusion, exendin‑4 may be associated with the upregulation of SERT expression via the AC/PKA signaling pathway.

Indexed as

AnimalsCell LineCyclic AMP-Dependent Protein KinasesEpithelial CellsExenatideGlucagon-Like Peptide 1Glucagon-Like Peptide-1 ReceptorIntestinesRatsSerotoninSerotonin Plasma Membrane Transport ProteinsSignal TransductionUp-RegulationCyclic AMP-Dependent Protein KinasesExenatideGlucagon-Like Peptide 1Glucagon-Like Peptide-1 ReceptorSerotoninSerotonin Plasma Membrane Transport Proteinsglucagon-like peptide-1iec-6 cellsirritable bowel syndromeserotonin transporter

Identifiers

PMID32319618
PMCPMC7057813
OpenAlexW3005485622

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.